1. Search Result
Search Result
Results for "

hyperammonemia

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Screening Libraries

4

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0711
    Carglumic Acid
    2 Publications Verification

    N-Carbamyl-L-glutamic acid

    Carbamoyl Phosphate Synthetase (CPS) Cancer
    Carglumic acid (N-Carbamyl-L-glutamic acid), a functional analogue of N-acetylglutamate (NAG) and a carbamoyl phosphate synthetase 1 (CPS1) activator, is used to treat acute and chronic hyperammonemia associated with NAG synthase (NAGS) deficiency.
    Carglumic Acid
  • HY-B1172
    Lactulose
    1 Publications Verification

    4-O-β-D-Galactopyranosyl-D-fructose

    Bacterial Interleukin Related DNA/RNA Synthesis Infection Inflammation/Immunology Endocrinology Cancer
    Lactulose is an orally active galactose-fructose disaccharide. Lactulose suppresses upregulation of TNF-α and IL-6. Lactulose decreases the degree of DNA damage. Lactulose exhibits many of the properties of other oligosaccharides, including increasing the numbers of Bifidobacteria in feces. Lactulose restores the structure and composition of the intestinal microbiota, mitigates inflammation, and suppresses inflammatory tumorigenesis in mice with colitis-associated cancer. Lactulose can be used in the research of constipation .
    Lactulose
  • HY-N0455B
    L-Arginine (L-glutamate)
    20+ Cited Publications

    (S)-(+)-Arginine (L-glutamate)

    Endogenous Metabolite NO Synthase Metabolic Disease
    L-Arginine L-glutamate ((S)-(+)-Arginine L-glutamate) is the nitrogen donor for synthesis of nitric oxide. L-Arginine L-glutamate can be used for upper gastrointestinal hypofunction or dysfunction like functional dyspepsia research .
    L-Arginine (L-glutamate)
  • HY-158161

    Amino acid Transporter Metabolic Disease
    SLC6A19-IN-1 is a potent and highly selective inhibitor and transport corrector of human SLC6A19 (IC50=47 nM). Furthermore, at a concentration of 35 μM, SLC6A19-IN-1 exhibits no activity against SLC1A5, SLC7A5, or SLC6A8. SLC6A19-IN-1 is applicable to research on phenylketonuria (PKU) and hyperphenylalaninemia. SLC6A19-IN-1 is also suitable for studies related to various metabolic disorders, including tyrosinemia, maple syrup urine disease, urea cycle disorders, and hyperammonemia .
    SLC6A19-IN-1
  • HY-B0711R

    N-Carbamyl-L-glutamic acid (Standard)

    Reference Standards Others Cancer
    Carglumic Acid (Standard) is the analytical standard of Carglumic Acid. This product is intended for research and analytical applications. Carglumic acid (N-Carbamyl-L-glutamic acid), a functional analogue of N-acetylglutamate (NAG) and a carbamoyl phosphate synthetase 1 (CPS1) activator, is used to treat acute and chronic hyperammonemia associated with NAG synthase (NAGS) deficiency.
    Carglumic Acid (Standard)
  • HY-131275R

    Drug Metabolite Reference Standards Others
    Carglumic Acid (Standard) is the analytical standard of Carglumic Acid. This product is intended for research and analytical applications. Carglumic acid (N-Carbamyl-L-glutamic acid), a functional analogue of N-acetylglutamate (NAG) and a carbamoyl phosphate synthetase 1 (CPS1) activator, is used to treat acute and chronic hyperammonemia associated with NAG synthase (NAGS) deficiency.
    Imatinib Impurity E (Standard)
  • HY-B1713

    (±)-Ornithine

    Endogenous Metabolite Ornithine decarboxylase (ODC) Drug Intermediate Metabolic Disease Cancer
    Ornithine ((±)-Ornithine) is a non-essential amino acid. Ornithine is an intermediate in urea cycle and acts as a substrate for these rate limiting enzymes ornithine transcarbomylase, ornithine aminotransferase and ornithine decarboxylase producing citrulline, proline and polyamines, respectively. Ornithine can be used in the research of hyperornithinemia, hyperammonemia, and cancer .
    Ornithine
  • HY-131691

    iGluR Calcium Channel Neurological Disease
    NMDAR blocker 1 is an NMDA receptor channel blocker with an IC50 of 5.0 μM. NMDAR blocker 1 exhibits fast on-off blockade kinetics and strong voltage dependence, and does not compete with glutamate or glycine. NMDAR blocker 1 prevents glutamate/NMDA-induced intracellular Ca 2+ overload, modulates the glutamate-nitric oxide-cGMP pathway. NMDAR blocker 1 prevents in vitro excitotoxic neurodegeneration of cultured cerebellar and hippocampal neurons. NMDAR blocker 1 attenuates excitotoxic insult in an mouse model of hyperammonemia-induced excitotoxicity. NMDAR blocker 1 can be used for the research of neurodegenerative diseases .
    NMDAR blocker 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: